A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Ontology highlight
ABSTRACT: Primary objectives: • to gather preliminary evidence of superior activity, of RO5083945 added to FOLFIRI versus FOLFIRI + cetuximab in terms of progression free survival (PFS) in patients with KRAS WT colorectal cancer
• to gather preliminary evidence of superior activity, of RO5083945 added to FOLFIRI versus FOLFIRI alone in terms of progression free survival (PFS) in patients with KRAS mutant colorectal cancer
Primary endpoints: The primary variable is PFS defined as the time between randomization and date of first documented disease progression or death, whichever occurs first.
DISEASE(S): Colorectal Cancer Metastatic,Metastatic Colorectal Cancer, Kras Wild-type (wt) Or Mutant, With Disease Progression After First Line Treatment With An Oxaliplatin-containing Regimen
PROVIDER: 2528754 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA